Bayesian hybrid dose-finding design in phase I oncology clinical trials

Statistics in Medicine

Volumn 30, Issue 17, 2011, Pages 2098-2108

  Yuan, Ying ^a   Yin, Guosheng ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bayes factor; Hypothesis testing; Model based; Model free; Robust

Indexed keywords

ARTICLE; BAYES THEOREM; CONTROLLED STUDY; DOSE CALCULATION; INTERMETHOD COMPARISON; MATHEMATICAL COMPUTING; MAXIMUM TOLERATED DOSE; PARAMETRIC TEST; PLOTS AND CURVES;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; MEDICAL ONCOLOGY; MODELS, STATISTICAL;

EID: 79960029322     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4164     Document Type: Article

References (22)

1. Chevret S. Statistical Methods for Dose-finding Experiments. Wiley: England, 2006.
2. Ting N. Dose Finding in Drug Development. Springer: Cambridge, 2006.
3. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989; 45:925-937.
4. Durham SD, Flournoy N, Rosenberger WF. A random walk rule for phase I clinical trials. Biometrics 1997; 53:745-760.
5. Leung D, Wang YG. An improved up-and-down design for phase I trials. Controlled Clinical Trials 2001; 22:126-138.
6. Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002; 58:171-177.
7. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46:33-48.
8. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1995; 14:1149-1161.
9. Møller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Statistics in Medicine 1995; 14:911-922.
10. Piantadosi S, Fisher J, Grossman S. Practical implementation of a modified continual reassessment method for dose finding trials. Cancer Chemotherapy and Pharmacology 1998; 41:429-436.
11. Heyd JM, Carlin PB. Adaptive design improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1999; 18:1307-1321.
12. Braun TM. The bivariate CRM: extending the CRM to phase I trials of two competing outcomes. Controlled Clinical Trials 2002; 23:240-255.
13. Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial. Clinical Trials 2006; 3:57-71.
14. Cheung YK, Chappell R. A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics 2002; 58:671-674.
15. Shen L, O'Quigley J. Consistency of continual reassessment method under model misspecification. Biometrika 1996; 83:395-405.
16. Yin G, Yuan Y. Bayesian model averaging continual reassessment method in phase I clinical trials. Journal of the American Statistical Association 2009; 104:954-968.
17. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim S, Fidler I, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. Journal of Clinical Oncology 2004; 16:3323-3329.
18. Goodman SN. Toward evidence-based medical statistics. Part 2: the Bayes factor. Annals of Internal Medicine 1999; 130:1005-1013.
19. Cheung YK. Sequential implementation of stepwise procedures for identifying the maximum tolerated dose. Journal of the American Statistical Association 2007; 102:1448-1461.
20. Jeffreys H. Theory of Probability (3rd edn). Oxford University Press: London, 1961.
21. Robertson T, Wright F, Dykstra R. Order Restricted Statistical Inference. Wiley: New York, 1988.
22. Cheung YK. Coherence principles in dose-finding studies. Biometrika 2005; 92:863-873.